ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	17.91B -0.2%
Revenue (ttm)	3.16B -7.1%
Net Income	136.95M -59.6%
EPS	0.17 -60.4%
Shares Out	790.74M
PE Ratio	133.24
Forward PE	56.63
Dividend	0.29 (1.28%)
Ex-Dividend Date	Jul 3, 2025

Volume	3,272,602
Average Volume	1,286,294
Open	22.00
Previous Close	21.70
Day's Range	21.90 - 22.80
52-Week Range	16.25 - 29.10
Beta	0.58
RSI	57.59
Earnings Date	May 4, 2026

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CDMO services, such as contract analytical testing services, s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2025, ScinoPharm Taiwan's revenue was 3.16 billion, a decrease of -7.13% compared to the previous year's 3.41 billion. Earnings were 136.95 million, a decrease of -59.64%.